William J. Tremaine

William J. Tremaine's AcademicInfluence.com Rankings

William J. Tremaine

Physics

#5982

World Rank

#7880

Historical Rank

#1692

USA Rank

physics Degrees

Download Badge

Physics

William J. Tremaine's Degrees

PhD Physics Stanford University
Masters Physics Stanford University
Bachelors Physics Stanford University

Why Is William J. Tremaine Influential?

(Suggest an Edit or Addition)

(See a Problem?)

William J. Tremaine's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. (1987) (2409)
The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. (2002) (939)
The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. (2004) (937)
Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. (2001) (923)
Pouchitis after ileal pouch-anal anastomosis: a Pouchitis Disease Activity Index. (1994) (662)
Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000 (2007) (652)
A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn's perianal fistulas. (2001) (558)
Correlation of C‐Reactive Protein With Clinical, Endoscopic, Histologic, and Radiographic Activity in Inflammatory Bowel Disease (2005) (549)
Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. (1996) (514)
Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. (2006) (483)
Infliximab in the Treatment of Severe, Steroid-Refractory Ulcerative Colitis: A Pilot Study (2001) (432)
American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. (2006) (385)
Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study. (2006) (372)
Early Postoperative Complications are not Increased in Patients with Crohn's Disease Treated Perioperatively with Infliximab or Immunosuppressive Therapy (2004) (370)
Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial (2008) (356)
Venous Thromboembolism in Inflammatory Bowel Disease (2004) (336)
Hereditary angioedema: a broad review for clinicians. (2001) (323)
Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients (2000) (308)
An Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Prior Loss of Response or Intolerance to Infliximab for Crohn's Disease (2004) (296)
Controlled trial of bowel rest and nutritional support in the management of Crohn's disease. (1988) (293)
Incidence and Prevalence of Crohn’s Disease and Ulcerative Colitis in Olmsted County, Minnesota From 1970 Through 2010 (2017) (284)
American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. (2006) (269)
Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. (2002) (263)
Transdermal Nicotine for Mildly to Moderately Active Ulcerative Colitis (1997) (251)
The epidemiology of microscopic colitis: a population based study in Olmsted County, Minnesota (2006) (249)
Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease (2001) (244)
Surgery in a Population-Based Cohort of Crohn's Disease From Olmsted County, Minnesota (1970–2004) (2012) (244)
Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide (2001) (199)
Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation (1998) (189)
Long-term fracture risk in patients with Crohn's disease: a population-based study in Olmsted County, Minnesota. (2002) (171)
Evaluation of Serologic Disease Markers in a Population-Based Cohort of Patients with Ulcerative Colitis and Crohn's Disease (2001) (162)
Incidental findings in imaging research: evaluating incidence, benefit, and burden. (2010) (162)
Management of Crohn's disease of the ileoanal pouch with infliximab (2003) (160)
Clinical Outcome Following Treatment of Refractory Inflammatory and Fistulizing Crohn's Disease With Intravenous Cyclosporine (1998) (158)
Microscopic colitis: a review (2002) (149)
Lymphocytic Colitis: clinical features, treatment, and outcomes (2002) (148)
Risk Factors for Colorectal Neoplasia in Inflammatory Bowel Disease: A Nested Case–Control Study From Copenhagen County, Denmark and Olmsted County, Minnesota (2007) (143)
The fate of low grade dysplasia in ulcerative colitis (2002) (142)
Autoimmune Disorders and Extraintestinal Manifestations in First-degree Familial and Sporadic Inflammatory Bowel Disease: A Case–Control Study (2004) (141)
Diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation. (2010) (140)
A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis. (1994) (136)
Incidence and Prognosis of Colorectal Dysplasia in Inflammatory Bowel Disease: A Population‐based Study from Olmsted County, Minnesota (2006) (136)
A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. (1994) (135)
Open‐label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab (2009) (132)
Renal and Urologic Complications of Inflammatory Bowel Disease (1998) (132)
Prevalence of penetrating disease and extraintestinal manifestations of Crohn's disease detected with CT enterography (2008) (131)
Successful management of Crohn's disease of the ileoanal pouch with infliximab. (1999) (131)
Risk of lymphoma in inflammatory bowel disease. (2000) (129)
Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. (2013) (127)
Azathioprine or 6-Mercaptopurine Before Colectomy for Ulcerative Colitis Is Not Associated With Increased Postoperative Complications (2002) (123)
Crohn’s Disease of the Esophagus: Clinical Features and Outcomes (2001) (121)
Cumulative Incidence and Risk Factors for Hospitalization and Surgery in a Population-based Cohort of Ulcerative Colitis (2013) (117)
Collagenous and lymphocytic colitis: subject review and therapeutic alternatives. (1995) (115)
Management of Internal Fistulas in Crohn's Disease (2002) (108)
Acute major gastrointestinal hemorrhage in inflammatory bowel disease. (1999) (108)
Sequential histologic evaluations in collagenous colitis (1992) (105)
Symptomatic overlap between irritable bowel syndrome and microscopic colitis. (2011) (103)
A population-based study of incidence, risk factors, clinical spectrum, and outcomes of ischemic colitis. (2015) (98)
The epidemiology of microscopic colitis in Olmsted County from 2002 to 2010: a population-based study. (2014) (98)
Collagenous colitis: mucosal biopsies and association with fecal leukocytes. (1995) (97)
Systematic review: the effectiveness of budesonide therapy for Crohn's disease (2002) (97)
Acute gastrointestinal bleeding. Experience of a specialized management team. (1992) (95)
Misdiagnosis of specific cytomegalovirus infection of the ileoanal pouch as refractory idiopathic chronic pouchitis (1999) (93)
Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059): an open‐label pilot study (2002) (92)
[American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease]. (2006) (88)
Risk of lymphoma in inflammatory bowel disease (2000) (86)
Cyclosporine enemas for treatment-resistant, mildly to moderately active, left-sided ulcerative colitis. (1993) (84)
Collagenous colitis: a clinicopathologic correlation. (1987) (82)
Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States (2002) (80)
Nonsteroidal anti-inflammatory drug-induced enteropathy: case discussion and review of the literature. (1995) (76)
AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis. (2019) (74)
Increased eosinophil granule proteins in gut lavage fluid from patients with inflammatory bowel disease. (1997) (73)
Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease (2002) (71)
Increased Risk of Acute Myocardial Infarction and Heart Failure in Patients With Inflammatory Bowel Diseases (2018) (70)
Analysis of Failure After Curative Irradiation of Extrahepatic Bile Duct Carcinoma (1992) (69)
Nicotine tartrate liquid enemas for mildly to moderately active left‐sided ulcerative colitis unresponsive to first‐line therapy: a pilot study (1997) (68)
Symptomatic overlap between irritable bowel syndrome and microscopic colitis (2007) (68)
Pouchitis disease course after orthotopic liver transplantation in patients with primary sclerosing cholangitis and an ileal pouch-anal anastomosis. (1995) (67)
Collagenous colitis and lymphocytic colitis. (2000) (66)
Benefit of Computed Tomography Enterography in Crohn's Disease: Effects on Patient Management and Physician Level of Confidence§† (2012) (65)
Risk of fracture in ulcerative colitis: a population-based study from Olmsted County, Minnesota. (2003) (64)
Outcomes of Patients With Microscopic Colitis Treated With Corticosteroids: A Population-Based Study (2013) (62)
Erythrocyte Mean Corpuscular Volume as a Surrogate Marker for 6-Thioguanine Nucleotide Concentration Monitoring in Patients with Inflammatory Bowel Disease Treated with Azathioprine or 6-Mercaptopurine (2003) (61)
Hidradenitis Suppurativa in Patients With Inflammatory Bowel Disease: A Population-Based Cohort Study in Olmsted County, Minnesota. (2016) (58)
Maternal and Fetal Outcome After Colectomy for Fulminant Ulcerative Colitis During Pregnancy: Case Series and Literature Review (2006) (58)
Update on the Natural Course of Fistulizing Perianal Crohn's Disease in a Population-Based Cohort. (2017) (57)
Cytomegalovirus Infection of the Ileoanal Pouch: Clinical Characteristics and Outcomes (2013) (57)
Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. (2002) (55)
Acute Pancreatitis in Patients With Crohn's Disease: Clinical Features and Outcomes (2005) (55)
Symptomatic Overlap Between Microscopic Colitis and Irritable Bowel Syndrome: A Prospective Study (2013) (54)
Endoscopic Factors in the Diagnosis of Colorectal Dysplasia in Chronic Inflammatory Bowel Disease (2005) (53)
The effectiveness of budesonide therapy for Crohn's disease. (2002) (52)
Adalimumab for Crohn's disease in clinical practice at Mayo clinic: The first 118 patients (2010) (51)
Combination Biologic Therapy in Inflammatory Bowel Disease: Experience from a Tertiary Care Center. (2020) (50)
Gastroduodenal Crohn's disease: medical management. (2003) (49)
Measurement of disease activity in ulcerative colitis: Interobserver agreement and predictors of severity (2011) (49)
Incidence of inflammatory bowel disease by race and ethnicity in a population-based inception cohort from 1970 through 2010 (2019) (49)
Lymphocytic Colitis Treated with Proctocolectomy and Ileal J-Pouch-Anal Anastomosis (2002) (47)
Validating Crohn's disease activity indices for use in assessing postoperative recurrence (2011) (46)
Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States. (2002) (46)
Natalizumab for moderate to severe Crohn's disease in clinical practice: The Mayo Clinic Rochester experience (2012) (46)
Fecal bile acids, short-chain fatty acids, and bacteria after ileal pouch-anal anastomosis do not differ in patients with pouchitis (1995) (45)
Budesonide in the treatment of inflammatory bowel disease: The first year of experience in clinical practice (2006) (45)
N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis (2002) (44)
The Natural History of Surgery for Ulcerative Colitis in a Population-Based Cohort from Olmsted County, Minnesota: 819 (2005) (41)
Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease (1999) (41)
Safety and tolerance of rHuIL-10 treatment in patients with mild/moderate active ulcerative colitis (1998) (39)
Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease. (2018) (39)
Effect of Medications on Risk of Cancer in Patients With Inflammatory Bowel Diseases: A Population-Based Cohort Study from Olmsted County, Minnesota. (2015) (39)
Transdermal nicotine decreases mucosal IL-8 expression but has no effect on mucin gene expression in ulcerative colitis. (1998) (39)
The role of the institutional review board in the oversight of the ethical aspects of human studies research. (2013) (38)
Pouchitis Is Associated with Mucosal Imbalance Between Interleukin‐8 and Interleukin‐10 (2000) (38)
Distribution of mesalamine enemas in patients with active distal ulcerative colitis. (1992) (38)
Review article: indeterminate colitis – definition, diagnosis and management (2006) (38)
Is Indeterminate Colitis Determinable? (2012) (37)
α1-Antitrypsin Deficiency and Inflammatory Bowel Diseases (2000) (37)
Perianal Crohn's disease findings other than fistulas in a population‐based cohort (2012) (37)
Incremental diagnostic yield of chromoendoscopy and outcomes in inflammatory bowel disease patients with a history of colorectal dysplasia on white-light endoscopy. (2016) (36)
Isolated Crohn's disease of the stomach. (1989) (36)
American Gastroenterological Association Institute Technical Review on the Medical Management of Microscopic Colitis. (2016) (34)
A prospective cohort study of practice guidelines in inflammatory bowel disease (2001) (34)
Incidence of Spondyloarthropathy in Patients with Crohn’s Disease: A Population-based Study (2012) (34)
Immune modulator therapy for microscopic colitis in a case series of 73 patients (2017) (33)
Antibiotic Use and New-Onset Inflammatory Bowel Disease in Olmsted County, Minnesota: A Population-Based Case-Control Study (2018) (33)
Pharmacokinetics of Nicotine Tartrate after Single‐Dose Liquid Enema, Oral, and Intravenous Administration (1997) (32)
Calcium absorption from milk in lactase-deficient and lactase-sufficient adults (1986) (32)
T1193 A Randomized, Double-Blind, Placebo-Controlled Trial of Budesonide for the Treatment of Active Lymphocytic Colitis (2009) (32)
Updated Incidence and Prevalence of Crohn’s Disease and Ulcerative Colitis in Olmsted County, Minnesota (1970-2010): ACG IBD Research Award: 1687 (2014) (31)
Fistulas to the urinary system in Crohn's disease: clinical features and outcomes. (2002) (31)
Fistulas to the urinary system in Crohn's disease: clinical features and outcomes (2002) (31)
A new syndrome of Crohn's disease and pachydermoperiostosis in a family. (1997) (28)
Development of a Microscopic Colitis Disease Activity Index: a prospective cohort study (2016) (28)
Melanosis coli in inflammatory bowel disease. (1998) (28)
Diagnosis and treatment of indeterminate colitis. (2011) (27)
N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis. (2002) (27)
Clinical Benefit of Capsule Endoscopy in Crohn's Disease: Impact on Patient Management and Prevalence of Proximal Small Bowel Involvement. (2018) (26)
Low Risk of Pneumonia From Pneumocystis jirovecii Infection in Patients With Inflammatory Bowel Disease Receiving Immune Suppression (2017) (26)
Refractory IBD: medical management. (1997) (25)
New-Onset Microscopic Colitis in an Ulcerative Colitis Patient After Fecal Microbiota Transplantation (2016) (25)
Incidence of Spondyloarthropathy in Patients with Ulcerative Colitis: A Population-based Study (2013) (25)
Early measles virus infection is associated with the development of inflammatory bowel disease (2000) (24)
Inflammatory Bowel Disease and Clostridium difficile-associated diarrhea: a growing problem. (2007) (24)
Alpha1-antitrypsin deficiency and inflammatory bowel diseases. (2000) (23)
The Natural History of Surgery for Crohnʼs Disease in a Population-Based Cohort from Olmsted County, Minnesota: 825 (2005) (23)
Hepatic duct stricture after radical radiation therapy for biliary cancer: recurrence or fibrosis? (1986) (22)
Bismuth subsalicylate tablets for chronic antibiotic-resistant pouchitis (1998) (20)
Microscopic colitis is not associated with cholecystectomy or appendectomy (2006) (20)
Early measles virus infection is associated with the development of inflammatory bowel disease. (2000) (19)
Miscellaneous Inflammatory and Structural Disorders of the Colon (2009) (19)
A case-matched study of laparoscopic proctocolectomy and ileal pouch-anal anastomosis (PC-IPAA) versus open PC-IPAA for ulcerative colitis (UC) (2001) (18)
Hereditary Angioedema as a Cause of Transient Abdominal Pain (2002) (18)
6-mercaptopurine therapy in selected cases of corticosteroid-dependent Crohn's disease. (1991) (18)
A Dose‐Ranging Study of Azathioprine Pharmacokinetics After Single‐Dose Administration of a Delayed‐Release Oral Formulation (1997) (18)
Overall and Cause‐Specific Mortality of Inflammatory Bowel Disease in Olmsted County, Minnesota, From 1970 Through 2016 (2018) (17)
Tacrolimus Salvage in Anti–Tumor Necrosis Factor Antibody Treatment-Refractory Crohn’s Disease (2013) (16)
Dexpanthenol enemas in ulcerative colitis: a pilot study. (1997) (16)
The safety profile of infliximab for Crohn's disease in clinical practice: The Mayo clinic experience in 500 patients (2003) (16)
Acute major lower GI Hemorrhage in inflammatory bowel disease (1997) (16)
Efficacy and safety of certolizumab pegol for Crohn's disease in clinical practice (2015) (16)
The natural history of fistulizing Crohn's disease: A population-based study (2000) (16)
Clinical features and complications of Crohn’s disease (2003) (16)
Pouchitis is associated with mucosal imbalance between interleukin-8 and interleukin-10. (2000) (16)
Clinical Outcome and Pharmacokinetics After Addition of Low‐Dose Cyclosporine to Methotrexate: A Case Study of Five Patients with Treatment‐Resistant Inflammatory Bowel Disease (2000) (14)
Diagnosing collagenous colitis: does it make a difference? (1999) (14)
Update on incidence and prevalence of Crohn's disease (CD) and ulcerative colitis (UC) in olmsted county, minnesota (2003) (14)
Chronic diarrhea due to surreptitious use of bisacodyl: case reports and methods for detection. (1993) (13)
Evaluation of perianal fistulas in patients with Crohn's disease. (2005) (13)
Maintenance of symptomatic remission in patients with Crohn's disease. (1993) (13)
Idiopathic inflammatory demyelinating disease of the central nervous system in patients with inflammatory bowel disease: retrospective analysis of 9095 patients (2015) (12)
The Epidemiology of Microscopic Colitis in Olmsted County, Minnesota: Population-Based Study from 2011-2019. (2021) (11)
Utility of perinuclear anti-neutrophil cytoplasmic antibodies (pANCA), anti-saccharomyces cerevisiae (ASCA), and anti-pancreatic antibodies (APA) as serologic markers in a population based cohort of patients with Crohn's disease (CD) and ulcerative colitis (UC) (2000) (11)
Treatment of erythema nodosum, aphthous stomatitis, and pyoderma gangrenosum in patients with IBD. (1998) (11)
The natural hisory of fistulizing Crohn's disease: A population-based study (2000) (11)
S1211 Clinical Benefit of CT Enterography in Suspected or Established Crohn's Disease: Impact On Patient Management and Physician Level of Confidence (2008) (11)
413 Age is not Associated With Adverse Events From Biologic Therapy in Patients With Inflammatory Bowel Disease (2010) (10)
Cumulative Length of Bowel Resection in a Population-Based Cohort of Patients With Crohn's Disease. (2016) (10)
Analysis of failure following curative irradiation of extrahepatic bile duct carcinoma (1986) (10)
Hospitalization Rates for Crohnʼs Disease Patients in Olmsted County, Minnesota, in the Pre-Biologic Era: 1004 (2007) (9)
S1184 Cumulative Incidence of and Risk Factors for Major Abdominal Surgery in a Population-Based Cohort of Crohn's Disease (2010) (8)
Macrotransaminase of aspartate aminotransferase (AST): a benign cause of elevated AST activity. (1990) (8)
Prevalence and Impact of Obesity on Disease-Specific Outcomes in a Population-Based Cohort of Patients with Ulcerative Colitis. (2021) (8)
Su1420 Ustekinumab Treatment for Crohn's Disease in Clinical Practice: Experience At a Tertiary Medical Center (2014) (8)
The Combination of Patient-Reported Clinical Symptoms and an Endoscopic Score Correlates Well with Health-Related Quality of Life in Patients with Ulcerative Colitis (2019) (7)
Cross-sectional study of IBD patients taking aza-thioprine (AZA) or 6-mercaptopurine (6-MP): Lack of correlation between disease activity and 6-thioguanine nucleotide (6TGN) concentration (2000) (7)
561 Inflammatory Bowel Disease and Non-Relaxing Pelvic Floor Dysfunction (2013) (7)
Comparative Outcomes of Younger and Older Hospitalized Patients with Inflammatory Bowel Disease Treated with Corticosteroids (2013) (7)
Su1353 Outcomes of Patients With Microscopic Colitis Treated With Bismuth Subsalicylate (2015) (7)
490 Postoperative Complications in a Population-Based Cohort of Crohn's Disease (2010) (6)
Bisphosphonates and the upper gastrointestinal tract: skeletal gain without visceral pain? (2002) (6)
Su1887 - Impact of Obesity on Future IBD-Related Complications in a Population-Based Cohort of Crohn's Disease (CD) and Ulcerative Colitis (UC) Patients (2018) (6)
A randomized, double-blind, placebo-controlied trial of subcutaneous etanercept (p75 souble tumor necrosis factor: FC fusion protein) in the treatment of moderate to severe Crohns' disease (2001) (6)
Transdermal Nicotine for Ulcerative Colitis: Reply (1997) (5)
Distinct Cutoff Values of Adalimumab Trough Levels Are Associated With Different Therapeutic Outcomes in Patients With Inflammatory Bowel Disease (2019) (5)
The safety profile of Azathioprine (AZA)/6-Mercaptopurine (6-MP) in the treatment of inflammatory bowel disease (IBD): a population-based study in Olmsted County, Minnesota (2003) (5)
P-033 YI Efficacy and Safety of Vedolizumab for Inflammatory Bowel Disease in Clinical Practice (2016) (5)
Treatment outcomes in lymphocytic collitis (2001) (5)
Inflammatory Bowel Disease: Clinical Aspects (2005) (5)
Equipoise, H. pylori, and Musketeers – Choosing an Appropriate Standard Clinical Care Regimen (2008) (5)
Validation of the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) and Its Correlation With Clinical Indices and Laboratory Measures of Disease Activity (2011) (5)
Periperative infliximab and/or immunomodulator therapy is not associated with increased postoperative complications in Crohn's disease (2003) (5)
Risk Factors for Ulcerative Colitis (UC) Surgery in a Population-Based Cohort: 987 (2007) (5)
A 1-Year Cross-sectional Inflammatory Bowel Disease Surveillance Colonoscopy Cohort Comparing High-definition White Light Endoscopy and Chromoendoscopy. (2020) (5)
Epidemiology and Clinical Outcomes of Patients With Inflammatory Bowel Disease Presenting With Acute Coronary Syndrome. (2020) (4)
Management of Crohn's disease (CD) of the ileoanal pouch with infixinab (2003) (4)
Extended-release Multimatrix Budesonide for Microscopic Colitis. (2017) (4)
S1096 Pre-Operative Infliximab Exposure and the Occurrence of Post-Operative Complications Following Proctocolectomy and Ileal Pouch-Anal Anastomosis (IPAA) for Ulcerative Colitis (UC) (2009) (4)
Pembrolizumab Induced Sclerosing Cholangitis. (2020) (4)
Ulcerative Colitis: Clinical Manifestations and Management (2016) (4)
Nine medico-legal pitfalls in inflammatory bowel disease in the United States. (2014) (4)
Ethical issues concerning therapeutic studies in inflammatory bowel disease (2007) (4)
Su1855 - Prevalence of Obesity and Influence on Phenotype within a Population-Based Cohort of Inflammatory Bowel Disease Patients (2018) (4)
Governance of Clinical Research (2012) (4)
Crohn's disease of the ileal pouch 16 years after proctocolectomy for ulcerative colitis. (2011) (3)
Biologics for inflammatory bowel disease: drug approval and monitoring in the United States. (2006) (3)
Maintenance Therapy in IBD (1998) (3)
Su1872 - Trends in the Prevalence of Overweight and Obesity at the Time of Inflammatory Bowel Disease Diagnosis: A Population-Based Study (2018) (3)
Ethical Issues, Safety, and Data Integrity in Clinical Trials (2005) (3)
Mo1236 Ileal Pouch Anal Anastomosis and Non-Relaxing Pelvic Floor Dysfunction (2014) (3)
Maintenance of remission in Crohn's disease: is 5'-aminosalicylic acid the answer? (1992) (3)
Inhibition of granuloma formation and prolonged survival in experimental schistosomiasis. (1972) (3)
Inflammatory bowel disease: From bench to bedside (1994) (3)
Failure to yield: drug resistance in inflammatory bowel disease. (2002) (3)
COLLAGENOUS COLITIS, BUT NOT LYMPHOCYTIC COLITIS, IS ASSOCIATED WITH CIGARETTE SMOKING: 359 (2004) (3)
Intravenous azathioprine in severe ulcerative colitis: a pilot study (2000) (3)
Mo1246 Hidradenitis Suppurativa in Patients With Inflammatory Bowel Disease: A Population-Based Study (2014) (2)
Incidence of Inflammatory Bowel Disease by Race and Ethnicity in a Population-Based Inception Cohort From 1970 Through 2010: 646 (2017) (2)
Mo1010 The Epidemiology of Microscopic Colitis: A Population-Based Update (2012) (2)
Open maintenance treatment with transdermal nicotine: Long-term results after a randomized, double-blind, placebo-controlled trial for active ulcerative colitis* (1998) (2)
A Cohort Study of the Age at Menopause in Female Patients With and Without Inflammatory Bowel Disease (2022) (2)
Incidence and Outcomes of Home Parenteral Nutrition in Patients With Crohn’s Disease in Olmsted County, Minnesota: 1710 (2014) (2)
Is there a threshold for the deleterious effect of smoking in Crohn's disease? (2008) (2)
6-TG for IBD: Simple, but safe? (2003) (2)
Investigation of a potential drug interaction between azathioprine (AZA)/6-mercaptopurine (6MP) and sulfasalazine (SAS), mesalamine (Pentasa) or balsalazide among patients with Crohn's disease (CD) (2000) (2)
990 Cumulative Probability and Outcomes of Anti-Tumor Necrosis Factor Use in Patients With Crohn's Disease: A Population-Based Study (2016) (2)
Chronic constipation: causes and management. (1990) (2)
Cigarette smoking should not be prescribed for the treatment of ulcerative colitis. (1998) (1)
Diarrhea: Diagnostic and Therapeutic Advances (2011) (1)
403: AN UPDATE ON INFLAMMATORY BOWEL DISEASE EPIDEMIOLOGY IN OLMSTED COUNTY, MINNESOTA FROM 1970 THROUGH 2019 (2022) (1)
W1095 Natalizumab Use in Clinical Practice in Patients with Moderate to Severe Crohn's Disease (2009) (1)
Ischemic proctitis with and without colonic involvement (1998) (1)
Tu1793 BILE ACID MALABSORPTION AND OUTCOMES AFTER TREATMENT WITH COLESEVELAM IN MICROSCOPIC COLITIS (2020) (1)
Su1191 Clinical Features and Outcomes of Patients With Microscopic Colitis Treated With Corticosteroids (2012) (1)
Budesonide CIR capsules once or twice daily in active Crohn's disease. A randomized placebo controlled study in the USA (2001) (1)
Medication-induced colonic disease, radiation proctitis, colonic metabolism, and the treatment of diarrhea and constipation (1992) (1)
TRANSDERMAL NICOTINE FOR ULCERATIVE COLITIS. AUTHORS' REPLY (1997) (1)
Inflammatory bowel disease workshop. Vail, Colorado, March 22 and 23, 1998. Maintenance therapy in IBD. (1998) (1)
Subject Review Maintenance of Symptomatic Remission in Patients With Crohn's Disease (1993) (1)
Tu1995 Rising Incidence of Ischemic Colitis in Olmsted County, Minnesota, 1976-2006: A Population-Based Epidemiological Study (2013) (1)
Case report (2017) (1)
Outcomes of Bismuth Subsalicylate Treatment in Patients With Microscopic Colitis: 116 (2017) (1)
Another Point of View—Reply (2011) (1)
Mo1842 - Clinical Experience with Vedolizumab Trough Levels in Inflammatory Bowel Disease (2018) (1)
Left-sided ulcerative colitis: True extent of disease and risk of pouchitis (2003) (1)
Letter: the definition of budesonide dependence in microscopic colitis—authors’ reply (2017) (1)
Risk Factors for Pouchitis after Ileal Pouch-Anal Anastomosis for Ulcerative Colitis or Indeterminate Colitis: A Population-Based Study: 1011 (2007) (1)
N-acetyltransferase (NAT) 1 and 2 genotypes do not predict response or toxicity to treatment with 5-ASA and sulfasalazine in a population-based cohort of patients with ulcerative colitis (UC) (2001) (1)
Mo1855 - Certolizumab Trough Levels and Antibodies in Inflammatory Bowel Disease: A Single-Center Experience (2018) (1)
W1240 Adalimumab for Crohn's Disease in Clinical Practice At An Academic Medical Center: the First 118 Patients (2008) (1)
Su1251 Outcomes of Microscopic Colitis and Smoking: A Population-Based Study (2013) (1)
Tu2006 Clinical Features and Outcomes of Ischemic Colitis in a Population-Based Cohort (2013) (1)
Mo1807 - The Short Inflammatory Bowel Disease Questionnaire Correlates well with Disease Activity and Patient-Reported Outcomes of Quality of Life, Work Productivity, Fatigue and Mood in Patients with Ulcerative Colitis (2018) (1)
Sequential and Combination Therapy for Ulcerative Colitis (2003) (1)
Fistulas to the bladder and urinary tract in Crohn’s disease (2000) (1)
Incidence of Post-Surgical Complications among Ulcerative Colitis (UC) Patients (Pts): A Population-Based Study: 986 (2007) (1)
Cancer Risk in a Population-Based Cohort of Inflammatory Bowel Disease: 1558 (2012) (1)
Certolizumab Trough Levels and Antibodies in Crohn Disease: A Single-Center Experience (2021) (1)
36 Proximal Extension of Left-Sided Ulcerative Colitis: A Population-Based Study (2008) (1)
Medicolegal Pitfalls in Inflammatory Bowel Disease Care (2012) (1)
Clinical Features and Outcomes of Cytomegalovirus Colitis or Pouchitis in Patients with Inflammatory Bowel Disease: 857 (2005) (1)
Effects of medications on the colon, diet and the colon, colonic vascular lesions, and radiation‐induced colonic injury (1993) (0)
Fr249 THE EPIDEMIOLOGY OF MICROSCOPIC COLITIS BETWEEN 2011-2019: AN OLMSTED COUNTY, MINNESOTA POPULATION-BASED STUDY (2021) (0)
Tu1524 Diagnostic Yield of Chromoendoscopy and Outcomes in IBD Patients With History of Dysplasia (2014) (0)
Treatment of Nonsteroidal Anti-Inflammatory Drug-Induced Enteropathy: In response (1995) (0)
Protection of research subjects. (2003) (0)
CURRENT MECHANISTIC AND CLINICAL CONCEPTS ON POUCHITIS: 530 (1997) (0)
Letter: effectiveness of split‐dose certolizumab pegol for Crohn's disease (2013) (0)
Alimentary tract and pancreas Controlled trial of bowel rest and nutritional support in the management of Crohn ' s disease (0)
S778 A Cross-Sectional Evaluation of the Prevalence of Pulmonary Diseases in Patients With Inflammatory Bowel Disease (2021) (0)
Preoperative infliximab does not decrease the area of resected bowel at surgery in Crohn's disease (2003) (0)
S958 Pharmacogene CYP1A2*1F Polymorphism Lowers Anti-TNF (infliximab) Response in Inflammatory Bowel Disease Patients (2021) (0)
Vulvar Crohn's Disease: Clinical Features and Outcomes (2021) (0)
Mucosal Ulcerative Colitis (1986) (0)
Episodic abdominal pain: an isolated gastrointestinal manifestation of hereditary angioedema (2000) (0)
Risk of Myocardial Infarction and Congestive Heart Failure in Inflammatory Bowel Disease: A Population-Based Inception Cohort Study (2017) (0)
“What Can I Do to Avoid Getting Too Much Radiation and What Imaging Test Is Right for Me?” Selecting the Best Imaging Test for the Right Patient and the Right Reason (2015) (0)
Case presentation: Refractory Crohn's disease (2000) (0)
The Influence of Immune Modifier Therapy on the Development of Non-Melanoma Skin Cancer in Patients with Crohnʼs Disease under Age Fifty: 934 (2007) (0)
Prevalence of Pulmonary Diseases in Association with Inflammatory Bowel Disease (2022) (0)
Issues in the Development of Practice Guidelines for Inflammatory Bowel Disease (1997) (0)
ALIMENTARY TRACT Lack of Effect of Intravenous Administration on Time to Respond to Azathioprine for Steroid-Treated Crohn’s Disease (1999) (0)
Prevalence of extraintestinal manifestations and autoimmune disorders in patients with familial and sporadic inflammatory bowel diseasehten (2000) (0)
S0875 Update on Clinical Outcome and Effectiveness of Corticosteroids in Patients With Crohn's Disease in a Population-Based Cohort (2020) (0)
Prevalence and Impact of Obesity in a Population-Based Cohort of Patients With Crohn's Disease. (2022) (0)
RE: Another point of view (2011) (0)
Frequency of Vitamin D Testing and Deficiency in Crohnʼs Disease: A Population-based Study: 1777 (2013) (0)
Low Risk of Pneumocytis Jirovecii Pneumonia in Patients with IBD Receiving Chronic Corticosteroid Therapy Does Not Justify Prophylaxis: A Population Based Study: 1276 (2011) (0)
Acute pancreatitis in Crohn's disease: Clinical features and outcomes (2003) (0)
P-040 Osteonecrosis in Inflammatory Bowel Disease: Clinical Features and Outcomes (2013) (0)
W1136 Efficacy of Oral Mesalamine for the Treatment of Crohn's Colitis: A Retrospective Study (2009) (0)
Case presentation: Crohn's disease with perianal involvement (2000) (0)
A prospective, case-controlled trial of practice guidelines in inflammatory bowel disease (IBD) (2000) (0)
Low Risk of Pneumocystis Jirovecii Pneumonia in Inflammatory Bowel Disease Patients Receiving Immunosuppressive Therapy: A Population-Based Cohort Study: 2016 ACG Fellows-In-Training Award (IBD Category): 574 (2016) (0)
A patient with acute pancreatitis, recurrent gastric bleeding, and an abdominal visceral aneurysm (1991) (0)
Cumulative Risk of Non-Melanoma Skin Cancer in a Population-Based Cohort of Inflammatory Bowel Disease: 1619 (2012) (0)
Clinical Benefit of Capsule Endoscopy in Crohnʼs Disease: Impact on Patient Management and Prevalence of Proximal Small Bowel Involvement: 635 (2016) (0)
Immunomodulatory treatment of microscopic colitis (2000) (0)
Effects of propiomazine and epinephrine on schistosoma granuloma formation. Abstr. (1970) (0)
Osteonecrosis in Inflammatory Bowel Disease: Clinical Features and Outcomes (2005) (0)
BUDESONIDE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE: A ONE YEAR EXPERIENCE IN CLINICAL PRACTICE AT THE MAYO CLINIC (2004) (0)
Tu1367 Effectiveness and Safety of Certolizumab Pegol for Crohn's Disease in a Large Cohort Followed at a Tertiary Care Center (2015) (0)
Incidence of Spondyloarthropathy in Patients with Crohn’s Disease: A Population-based Study (2011) (0)
Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059): an open-label pilot study*1 (2001) (0)
Pentoxifylline Use in Microscopic Colitis: A Case Series: 671 (2017) (0)
Book Reviews (1946) (0)
Intestinal lumen and tissue pharmacokinetics of methotrexate in inflammatory bowel disease: Subcutaneous methotrexate achieves pharmacologically active concentrations in the rectum (1998) (0)
Clinical Gastroenterology, Richard G. Farmer, Edgar Achkar, Bertram Fleshier (Eds.). Raven Press, New York (1983), 614, with illus, $55 (1984) (0)
Hepatotoxicity of 6-Mercaptopurine and Azathioprine: The authors reply (1994) (0)
Hereditary angioedema and hormones. Authors' reply (2002) (0)
Immunosuppressant Use in Chronic, Active Microscopic Colitis in Clinical Practice (2017) (0)
CMV Infection of the Pouch : Clinical Characteristics , Diagnosis , Treatment , and Outcome (0)
Pouchitis and Other Pouch Dysfunction Syndromes after Ileal Pouch-Anal Anastomosis for Ulcerative Colitis or Indeterminate Colitis: A Population-Based Study: ACG IBD Award: 1220 (2011) (0)
Risk Factors and Outcomes of Ischemic Colitis in a Population-based Cohort: Presidential Poster: 559 (2013) (0)
Clinical spectrum and outcomes in a population-based cohort with ischemic colitis (2003) (0)
Refractory IBD : medical management : Clinical topics in inflammatory Bowel disease (1997) (0)
Idiopathic Inflammatory Demyelinating Disease of the Central Nervous System in Patients With Inflammatory Bowel Disease: 1685 (2014) (0)
Mo1312 Cumulative Length of Bowel Resection in a Population-Based Cohort of Crohn's Disease (2013) (0)
The Role of Anti-Tumor Necrosis Factor Therapy in Microscopic Colitis: 676 (2017) (0)
Su1208 Effectiveness of Split-Dose Certolizumab Pegol for the Treatment of Crohn's Disease: Experience At a Tertiary Care Center (2013) (0)
Infliximab for Ulcerative Colitis in Clinical Practice: Single-Center Experience: 1184 (2011) (0)
Non-A, Non-B hepatitis with necrotizing vasculitis and other extrahepatic manifestations. (1985) (0)
Tu1225 Upper Gastrointestinal Tract Involvement in Crohn's Disease Requiring Anti-TNF Therapy: Clinical Characteristics (2012) (0)
W1158 Inter-Observer Agreement and Predictors of Assessment of Overall Endoscopic Severity in Ulcerative Colitis (UC) (2009) (0)
P167 VEDOLIZUMAB TROUGH LEVELS AND ANTIBODIES IN INFLAMMATORY BOWEL DISEASE: UPDATED INITIAL EXPERIENCE (2018) (0)
Cumulative Incidence of Cancer in a Population-based Cohort of Inflammatory Bowel Disease: 1718 (2013) (0)
Incidence and Outcomes of Home Parenteral Nutrition in Patients With Crohn Disease in Olmsted County, Minnesota (2020) (0)
25 Incidence of Spondyloarthropathy in Patients With Ulcerative Colitis: A Population-Based Study (2012) (0)
ENDOSCOPIC FACTORS IN THE DIAGNOSIS OF COLORECTAL DYSPLASIA IN CHRONIC INFLAMMATORY BOWEL DISEASE: 812 (2004) (0)
Su1351 Quality of Life in Lymphocytic and Collagenous Colitis (2015) (0)
Fistulas to the bladder and urinary tract in Crohn's disease (2000) (0)
Changes in Mortality in Patients with Inflammatory Bowel Disease: A Population-Based Inception Cohort Study (2017) (0)
Inflammatory bowel disease: From bench to bedside: Edited by Stephan Targan and Fergus Shanahan. 795 pp. $120.00. Williams & Wilkins, Baltimore, Maryland, 1994. ISBN 0-683-081101 (1994) (0)
Analysis of Risk Factors for Avascular Necrosis in Inflammatory Bowel Disease: 1667 (2014) (0)
Evaluation of the Combination of Fecal Lactoferrin and Fecal Anti-Saccharomyces Cerevesiae Antibodies To Detect Active Crohnʼs Disease: 1001 (2007) (0)
Colitis, Collagenous and Lymphocytic (2004) (0)
MICROSCOPIC COLITIS IS NOT ASSOCIATED WITH AN INCREASED RISK OF COLORECTAL CANCER: 358 (2004) (0)
P-082 YI Predictors of Health Related Quality of Life in Microscopic Colitis (2016) (0)
Dietary fiber: By B. McNamee and V. Mansour-McNamee. 77 pp., 12 figures. Softcover. $4.00. Urban and Schwarzenberg, New York, New York, 1985 (1985) (0)
Derivation of a Microscopic Colitis Disease Activity Index (MCDAI): 1294 (2011) (0)
Authorship and Industry Sponsorship in Treatment Trials in Inflammatory Bowel Disease: 946 (2007) (0)
Don't ASCA silly question (2008) (0)
Inflammatory bowel disease: Keys to diagnosis and treatment (1998) (0)
Hereditary Angioedema and Hormones—Reply (2002) (0)
Other colonic disorders (1990) (0)
Mo1802 - The Relationship Between Patient-Reported Clinical Outcomes, Endoscopic Inflammation and Health-Related Quality of Life in Patients with Ulcerative Colitis (2018) (0)
Su1982 AN UPDATE ON CLINICAL OUTCOME AND EFFECTIVENESS OF CORTICOSTEROIDS FOR TREATMENT OF ULCERATIVE COLITIS IN A POPULATION-BASED COHORT (2020) (0)
Regulatory and Ethical Issues in Inflammatory Bowel Disease Research INFLAMMATORY BOWEL DISEASE: A PRACTICAL APPROACH, SERIES #17 (2006) (0)
Case presentation: Steroid refractory colitis (2000) (0)
Case presentation: Postoperative prophylaxis (2000) (0)
S763 A Cohort Study of the Age of Menopause in Female Patients With and Without Inflammatory Bowel Disease (2021) (0)
Osteonecrosis in Inflammatory Bowel Disease: Clinical Features, Risk Factor Analysis, and Outcomes. (2022) (0)
Bariatric Surgery in Patients with Crohnʼs Disease and Extreme Obesity: 525 (2007) (0)
Update: inflammatory bowel disease. (1989) (0)
Pouchitis risk: flip the coin? (1997) (0)
Su1399: DOES THE ETIOLOGY OF CIRRHOSIS IMPACT THROMBOEMBOLIC RISK? (2022) (0)
Alimentary tract andpancreas Controlled trial ofbowelrest andnutritional support inthemanagement ofCrohn's disease (1988) (0)
farmnaceutica composition for the treatment of intestinal disease inflmatoria. (1998) (0)
The Safety Profile of Biologic Therapy in Older IBD Patients - A Pilot Study: 1242 (2009) (0)
Effectiveness of Hepatitis B Vaccination for Patients With Inflammatory Bowel and Celiac Disease. (2023) (0)
Higher Therapeutic Tacrolimus Trough Levels Are Associated with Fewer Surgical Resections in Crohnʼs Disease Patients Refractory to Anti-TNFα Therapy: 1211 (2010) (0)
Recent studies on colonic infections, collagenous and microscopic colitis, short‐chain fatty acids, brown bowel syndrome, abdominal epilepsy, and diabetic diarrhea (1991) (0)
Mo1178 Risk of Lymphoma and Leukemia Among Inflammatory Bowel Disease Patients Using Immunomodulators: Population-Based Cohort Study (2014) (0)
A pharmaceutical composition for the treatment of inflammatory bowel disease (1998) (0)
P128 INCIDENCE AND OUTCOMES OF HOME PARENTERAL NUTRITION IN PATIENTS WITH CROHN’S DISEASE IN OMLSTED COUNTY, MINNESOTA, USA (2020) (0)
The Association of Serologic Inflammatory Markers with Microscopic Colitis Disease Activity: 420 (2011) (0)
Tu1923 The Effect of Antigen Oxidation and TGF on NaïVE T Cell Phenotype and Proliferation (2012) (0)
Indeterminate colitis – The role of wireless capsule endoscopy: author's reply (2007) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With William J. Tremaine?

William J. Tremaine is affiliated with the following schools:

University of Mississippi
California Institute of Technology
Mayo Clinic Graduate School of Biomedical Sciences
Vanderbilt University
Stanford University